Contact
searchSearch
HMP Global
Login

HER2 News

News
Sevabertinib Demonstrates Robust Antitumor Activity in HER2-Mutated Non-Small Cell Lung Cancer
12/04/2025
Stephanie Holland
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2 SOHO-01 trial demonstrate that sevabertinib, an anti-HER2 tyrosine kinase inhibitor, shows promising antitumor activity among patients with locally advanced or metastatic HER2-mutated non–small cell lung cancer...
Results from the phase 1/2...
12/04/2025
Oncology
FDA Approval
FDA Grants Accelerated Approval to Sevabertinib for HER2-Mutated Non-Squamous NSCLC
11/19/2025
Emily Estrada
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated approval to sevabertinib for adults with locally advanced or metastatic non-squamous non–small cell lung cancer harboring HER2 tyrosine kinase domain activating mutations who have received prior systemic...
The FDA has granted accelerated...
11/19/2025
Oncology
FDA Approval
FDA Approves First Interchangeable Biosimilar to Pertuzumab for HER2-Positive Breast Cancer
11/13/2025
Stephanie Holland
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb as the first interchangeable pertuzumab biosimilar for the treatment of patients with HER2-positive metastatic breast cancer.
The FDA approved pertuzumab-dpzb...
11/13/2025
Oncology
News
Lower Ribociclib Dose Maintains Efficacy With Reduced Toxicity in Advanced HR-Positive, HER2-Negative Breast Cancer
11/07/2025
Stephanie Holland
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE trial show that a 400 mg starting dose of ribociclib, combined with a nonsteroidal aromatase inhibitor, reduced dose-dependent adverse events while maintaining efficacy vs the standard dose in HR-positive,...
Results from the phase 2 AMALEE...
11/07/2025
Oncology
News
Culmerciclib Plus Fulvestrant for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/29/2025
Stephanie Holland
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Primary analysis results from the phase 3 CULMINATE-2 trial show that adding culmerciclib to fulvestrant significantly improves outcomes among previously untreated patients with HR-positive, HER2-negative locally advanced or metastatic breast...
Primary analysis results from...
10/29/2025
Oncology
News
Trastuzumab Deruxtecan Provides Significant Clinical Benefit Over Trastuzumab Emtansine in HER2-Positive Early Breast Cancer
10/18/2025
Stephanie Holland
Results from the phase 3 DESTINY-Breast05 trial show trastuzumab deruxtecan significantly improved invasive disease-free survival compared to trastuzumab emtansine among patients with HER2-positive early breast cancer.
Results from the phase 3 DESTINY-Breast05 trial show trastuzumab deruxtecan significantly improved invasive disease-free survival compared to trastuzumab emtansine among patients with HER2-positive early breast cancer.
Results from the phase 3...
10/18/2025
Oncology
News
Neoadjuvant T-DXd-THP Improves Pathologic Response and Safety vs ddAC-THP in High-Risk HER2-Positive Early Breast Cancer
10/18/2025
Janelle Bradley
Neoadjuvant trastuzumab deruxtecan plus trastuzumab, pertuzumab, and docetaxel (T-DXd-THP) significantly improved pathologic complete response rates (pCR), showed early favorable event-free survival, and reduced severe toxicity compared to...
Neoadjuvant trastuzumab deruxtecan plus trastuzumab, pertuzumab, and docetaxel (T-DXd-THP) significantly improved pathologic complete response rates (pCR), showed early favorable event-free survival, and reduced severe toxicity compared to...
Neoadjuvant trastuzumab...
10/18/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Novel Antibody-Drug Conjugate Showed Promise Among Patients With Advanced Breast Cancer With Low HER2 Expression
09/25/2025
Allison Casey
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
In a phase 2 study, MRG002 demonstrated manageable safety profile and promising anti-tumor activity among patients with locally advanced or metastatic breast cancer with low HER2 expression.
In a phase 2 study, MRG002...
09/25/2025
Oncology
News
Sequential HER2-Targeted Therapy Following Trastuzumab Deruxtecan Discontinuation Among Patients With HER2-Positive Metastatic Breast Cancer
09/12/2025
Stephanie Holland
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy following trastuzumab deruxtecan discontinuation demonstrated clinical promise among patients with HER2-positive metastatic breast cancer who responded to T-DXd however discontinued treatment due to adverse...
Sequential HER2-targeted therapy...
09/12/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use